ED90 of Remimazolam Loading Dose for Sedation in Patients Under Monitored Anesthetic Care

Asan Medical Center

Status and phase

Completed

Phase 4

Conditions

Remimazolam

Orthopedic Procedures

Sedatives

Treatments

Drug: Remimazolam

Study type

Interventional

Funder types

Other

Identifiers

NCT05340335

S2021-2407-0002

Details and patient eligibility

About

Currently used drugs for monitored general anesthesia include propofol, midazolam, and dexmedetomidine. Each drug has different advantages and disadvantages. Remimazolam causes a relatively small decrease in blood pressure, and it has no injection pain. In addition, remimazolam has a very short onset time, and even after the continuous infusion, the onset of remimazolam is fast, and even after continuous injection, the effect disappeared very quickly due to the short context-sensitive half time. nd through continuous infusion, the patient's depth of anesthesia can be maintained constant. In addition, the short duration of action and the ability to quickly reverse the effect of flumazenil suggest that remimazolam can be used effectively under general anesthesia as well as under general anesthesia. Remimazolam can be used as a continuous infusion for general anesthesia. However, it has also been reported to be used for sedation by continuous infusion or divided intravenous infusion. However, the effective infusion dose of remimazolam for supervised general anesthesia without mechanical ventilation has not been established.

In this study, the ED90 of the loading dose to induce loss of consciousness in patients when supervised general anesthesia is performed through continuous infusion of Remimazolam is to be obtained.

Enrollment

50 patients

Sex

All

Ages

19 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

ASA PS 1-3
Patients who are scheduled to undergo upper/lower limb surgery under the monitored anesthetic care with remimazolam

Exclusion criteria

Patients who refuse to participate in this study
Patients with hypersensitivity to benzodiazepine or flumazenil
Patients with severe renal/hepatic disease
Patients with drug/alcohol abuse
Patients who take antidepressants, anticonvulsants, psychoactive drugs chronically
Patients with difficulty in communication
Patients with severe obstructive sleep apnea or other airway problems
Patients contraindicated to regional anesthesia
Patients judged to be inappropriate for this study